Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b

Journal of Neurology

Volumn 248, Issue 11, 2001, Pages 979-986

  Narayanan, Sridar ^a   De Stefano, Nicola ^a   Francis, Gordon S ^a   Arnaoutelis, Rozie ^a   Caramanos, Zografos ^a   Collins, D Louis ^a   Pelletier, Daniel ^a   Arnason, Barry G W ^b   Antel, Jack P ^a   Arnold, Douglas L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Axons; Interferon beta; Magnetic resonance spectroscopy; Multiple sclerosis; N acetylaspartate

Indexed keywords

BIOLOGICAL MARKER; CREATINE; INTERFERON BETA SERINE; N ACETYLASPARTIC ACID;

ARTICLE; AXONAL INJURY; BRAIN SIZE; CELL METABOLISM; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; MULTIPLE SCLEROSIS; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SCORING SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ADULT; ASPARTIC ACID; BIOLOGICAL MARKERS; DIFFUSE AXONAL INJURY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0035788425     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170052     Document Type: Article

References (61)

1. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41(1):81-91
2. Arnold DL. Reversible reduction of N-acetylaspartate after acute central nervous system damage. In: Society of Magnetic Resonance in Medicine; 1992; 1992. p. 643
3. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Res Med 1990; 14:154-159
4. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996; 7(8):1397-1400
5. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999; 45(2):247-250
6. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000; 74(1):254-262
7. Brenner RE, Munro PM, Williams SC, Bell JD, Barker GJ, Hawkins CP, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993; 29:737-745
8. Bruhn H, Frahm J, Merboldt KD, Hanicke W, Hanefeld F, Christen HJ, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992; 32(2):140-150
9. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141:554-555, 557-558
10. Collins DL, Narayanan S, Caramanos Z, De Stefano N, Tartaglia MC, Arnold DL. Relation of cerebral atrophy in multiple sclerosis to severity of disease and axonal injury. American Academy of Neurology, 52nd Annual Meeting, San Diego, CA. Neurology 2000; 54 Supp. 3:A17
11. Dautry C,Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3- nitropropionic acid. J Cereb Blood Flow Metab 2000; 20(5):789-799
12. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117:49-58
13. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995; 64(2):742-748
14. de Beer R, van Ormondt D. Analysis of NMR data using time domain fitting procedures. In: NMR Basic Principles and Progress. Berlin: Springer-Verlag; 1992. p. 204-248
15. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylas-partate after acute brain injury. Magn Reson Med 1995; 34(5):721-727
16. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38:901-909
17. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999; 122(Pt 10):1933-1939
18. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2000; In Press
19. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120(Pt 3):393-399
20. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43(6):809-814
21. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995; 45(3 Pt 1):478-482
22. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI [see comments]. Neurology 2000; 54(4):807-812
23. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121(Pt 1):103-113
24. Haase A, Frahm J. Multiple chemical shift selective NMR imaging using stimulated echoes. J. Magn. Reson. 1985(64):94-102
25. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36:157-165
26. Larsson HB, Christiansen P, Jensen M, Frederiksen J, Heltberg A, Olesen J, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1991; 22(1):23-31
27. Lassmann H. The pathology of multiple sclerosis and its evolution. Philos Trans R Soc Lond B Biol Sci 1999; 354(1390):1635-1640
28. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiplesclerosis. Neurology 1991; 41:1251-1256
29. Matthews PM, Cianfaglia L, McLaurin J, Cashman N, Sherwin D, Arnold D, et al. Demonstration of reversible decreases in N-Acetylaspartate (NAA) in a neuronal cell line: NAA decreases as a marker of sublethal neuronal dysfunction [abstract]. Proc Soc Magn Reson Med 1995; 1:147
30. Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18(3):327-336
31. McDonald WI. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. [Review]. J Neuropathol Exp Neurol 1994; 53:338-343
32. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. NeuroReport 1991; 2:131-134
33. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119(Pt1):225-237
34. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994 Aug 13; 344(8920):486]. Lancet 1994; 344(8918):298-301
35. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 3(1):56-71
36. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41(3):385-391
37. Ordidge RJ, Mansfield P, Lohman JA, Prime SB.Volume selection using gradients and selective pulses. Ann N Y Acad Sci 1987; 508:376-385
38. Pan JW, Hetherington HP,Vaughan JT, Mitchell G, Pohost GM, Whitaker JN. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med 1996; 36(1):72-77
39. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979; 184(3):539-546
40. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group [see comments]. Neurology 1993; 43:662-667
41. Pike GB, De Stefano N, Narayanan S, Francis GS, Antel JP, Arnold DL. Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 1999; 20(5):829-837
42. Pike GB, De Stefano N, Narayanan S, Worsley KJ, Pelletier D, Francis GS, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images [In Process Citation]. Radiology 2000; 215(3):824-830
43. Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR 1998; 19(9):1705-1713
44. Rooney WD, Goodkin DE, Schuff N, Meyerhoff DJ, Norman D, Weiner MW. 1H MRSI of normal appearing white matter in multiple sclerosis. Multiple Sclerosis 1997; 3(4):231-237
45. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group [In Process Citation]. Neurology 1999; 53(8):1698-1704
46. Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998; 64(2):204-212
47. Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients [In Process Citation]. Brain 1999; 122(Pt 3):513-521
48. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis [see comments]. Brain 1998; 121(Pt 12):2221-2228
49. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH. Evidence of widespread subtle blood-brain barrier dysfunction associated with progressive MS. Proc Soc Magn Reson Med 1999; 1:628
50. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45:37-45
51. Stewart VC, Land JM, Clark JB, Heales SJ. Pretreatment of astrocytes with in-terferon-alpha/beta prevents neuronal mitochondrial respiratory chain damage. J Neurochem 1998; 70(1):432-434
52. Stewart VC, Giovannoni G, Land JM, McDonald WI, Clark JB, Heales SJ. Pre-treatment of astrocytes with interferon-alpha/beta impairs interferon-gamma induction of nitric oxide synthase. J Neurochem 1997; 68(6):2547-2551
53. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37(5):611-619
54. The IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661
55. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis [see comments]. N Engl J Med 1998; 338(5):278-285
56. Truckenmiller ME, Namboodiri MA, Brownstein MJ, Neale JH. N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem 1985; 45(5):1658-1662
57. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 59:55-61
58. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13:981-989
59. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999; 46(1):79-87
60. Waxman SG. Demyelinating diseases-new pathological insights, new therapeutic targets [editorial; comment]. N Engl J Med 1998; 338(5):323-325
61. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18(2):601-609